Co-administration of CpG oligonucleotides enhances the late affinity maturation process of human anti-hepatitis B vaccine response (Q38334354)

2 September 2017

Co-administration of CpG oligonucleotides enhances the late affinity maturation process of human anti-hepatitis B vaccine response (English)

1 reference

2 September 2017

1

Claire-Anne Siegrist

1 reference

2 September 2017

Maria Pihlgren

2

1 reference

2 September 2017

Chantal Tougne

3

1 reference

2 September 2017

Sue M Efler

4

1 reference

2 September 2017

Mary Lou Morris

5

1 reference

2 September 2017

Mohammed J AlAdhami

6

1 reference

2 September 2017

D William Cameron

7

1 reference

2 September 2017

Curtis L Cooper

8

1 reference

2 September 2017

Jenny Heathcote

9

1 reference

2 September 2017

Heather L Davis

10

1 reference

2 September 2017

Paul-Henri Lambert

11

1 reference

2 September 2017

language of work or name

English

0 references

publication date

1 December 2004

1 reference

2 September 2017

1 reference

2 September 2017

23

1 reference

2 September 2017

5

1 reference

2 September 2017

615-622

1 reference

In situ studies of the primary immune response to (4-hydroxy-3-nitrophenyl)acetyl. II. A common clonal origin for periarteriolar lymphoid sheath-associated foci and germinal centers

2 September 2017

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.07.014

Antigen-driven B cell differentiation in vivo

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.07.014

Somatic mutation and the maturation of immune response to 2-phenyl oxazolone

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.07.014

The role of somatic hypermutation in the generation of antibody diversity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.07.014

Intraclonal generation of antibody mutants in germinal centres

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.07.014

Maturation of the immune response in germinal centers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.07.014

Life and death in germinal centers (redux).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.07.014

Molecular events during maturation of the immune response to oxazolone

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.07.014

Kinetic maturation of an immune response

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.07.014

In situ studies of the primary immune response to (4-hydroxy-3-nitrophenyl)acetyl. V. Affinity maturation develops in two stages of clonal selection.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.07.014

Immune effects and mechanisms of action of CpG motifs

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.07.014

Rescue of B cells from apoptosis by immune stimulatory CpG DNA.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.07.014

CpG DNA rescues B cells from apoptosis by activating NFkappaB and preventing mitochondrial membrane potential disruption via a chloroquine-sensitive pathway

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.07.014

CpG motifs in bacterial DNA trigger direct B-cell activation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.07.014

CpG motifs as immune adjuvants

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.07.014

CpG DNA can induce strong Th1 humoral and cell-mediated immune responses against hepatitis B surface antigen in young mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.07.014

Adjuvant effects of CpG oligodeoxynucleotides on responses against T-independent type 2 antigens

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.07.014

CpG motifs in bacterial DNA and their immune effects

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.07.014

Immunostimulatory sequence oligodeoxynucleotide-based vaccination and immunomodulation: two unique but complementary strategies for the treatment of allergic diseases

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.07.014

The measurement of relative antibody affinity by ELISA using thiocyanate elution

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.07.014

Correlation between the avidity of mouse-human chimeric IgG subclass monoclonal antibodies measured by solid-phase elution ELISA and biospecific interaction analysis (BIA)

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.07.014

Antibody avidity as a surrogate marker of successful priming by Haemophilus influenzae type b conjugate vaccines following infant immunization.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.07.014

Generation of adult-like antibody avidity profiles after early-life immunization with protein vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.07.014

Maintenance of serological memory by polyclonal activation of human memory B cells.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.07.014

Distinct response of human B cell subpopulations in recognition of an innate immune signal, CpG DNA.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.07.014

Role of BCR affinity in T cell dependent antibody responses in vivo

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.07.014

Germinal center reaction.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.07.014

CpG-motifs enhance initial and sustained primary tetanus-specific antibody secreting cell responses in spleen and bone marrow, but are more effective in adult than in neonatal mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.07.014

Virus neutralization by germ-line vs. hypermutated antibodies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.07.014

Comparison of two single-chain antibodies that neutralize canine parvovirus: analysis of an antibody-combining site and mechanisms of neutralization

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.07.014

The strong positive correlation between effective affinity and infectivity neutralization of highly cross-reactive monoclonal antibody IIB4, which recognizes antigenic site B on influenza A virus haemagglutinin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.07.014

Non-germ-line encoded residues are critical for effective antibody recognition of a poorly immunogenic neutralization epitope on glycoprotein B of human cytomegalovirus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.07.014

Protection against measles virus-induced encephalitis by anti-mimotope antibodies: the role of antibody affinity.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.07.014

In vitro neutralization of hepatitis B virus by monoclonal antibodies against the viral surface antigen

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.07.014

Cell Selection by Antigen in the Immune Response

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.07.014

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1016/J.VACCINE.2004.07.014

1 reference

2 September 2017

1 reference